MBTPS1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2742702	1.00	20/20
SCHEMBL4210498	0.59	15/20
SCHEMBL6412026	0.48	9/20
SCHEMBL7262616	0.52	7/20
SCHEMBL4525050	0.48	7/20
SCHEMBL2458994	0.48	7/20
SCHEMBL3736662	0.43	7/20
SCHEMBL3736663	0.43	7/20
Hydrochloric Acid (SCHEMBL7136730)	0.47	6/20
SCHEMBL7937465	0.46	6/20
Hydrochloric Acid (SCHEMBL7937463)	0.46	6/20
SCHEMBL4919198	0.51	5/20
SCHEMBL340465	0.50	5/20
SCHEMBL4634597	0.50	5/20
Hydrochloric Acid (SCHEMBL6417059)	0.46	5/20
SCHEMBL3543699	0.41	5/20
SCHEMBL3543704	0.41	5/20
SCHEMBL4634209	0.53	4/20
SCHEMBL4634249	0.53	4/20
SCHEMBL653142	0.52	4/20

Clinical trials — most relevant to MBTPS1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)	PHASE3	UNKNOWN
Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.	PHASE3	COMPLETED
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer	PHASE2	UNKNOWN
Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus	PHASE2	UNKNOWN
Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt)	PHASE1/PHASE2	RECRUITING
Serum Betatrophin Levels and Its Influencing Factors in Patients With Hyperthyroidism	nan	UNKNOWN
Observational Study to Assess Glycosylated Hemoglobin Changes After 6 Months of Treatment With Pioglitazone.	nan	COMPLETED
MERC Proteins in Saliva and GCF in Periodontal Disease (ELISA Study)	nan	COMPLETED
New Genes Involved in Molecular Etiology of Rett Syndrome Through DNA Microarray Comparative Genomic Hybridization	nan	COMPLETED
Tecfidera Diffusion Tensor Imaging	nan	COMPLETED
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
Familial Partial Lipodystrophy Study	nan	COMPLETED
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases	nan	UNKNOWN
Nuclear Myosin VI - a Therapeutic Target in Breast Cancer	nan	UNKNOWN
Identification of Genetic Variants Associated With Unexpected Infant Death Syndrome	nan	RECRUITING
Molecular Genetic Epidemiology of Endocardial Cushion Defects - SCOR in Pediatric Cardiovascular Disease	nan	COMPLETED
Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins.	nan	UNKNOWN
Impact of Seasonal Malaria Chemoprevention on Immunity Against Malaria Among Children in Northern Benin	nan	COMPLETED
Chronic Obstructive Pulmonary Disease Gene Localization	nan	COMPLETED
MMP Polymorphisms and Acute Coronary Syndromes	nan	COMPLETED
Cerebellar Mutism Syndrome Study	nan	RECRUITING
Linkage Study in Familial Pulmonary Fibrosis	nan	COMPLETED
Mapping Novel Disease Genes for Dilated Cardiomyopathy	nan	COMPLETED
Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes	nan	COMPLETED
Comparison of Two Methods to Diagnose Coronary Artery Disease	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Epigenetic Testing for Breast Cancer Risk Stratification	nan	COMPLETED
Characterization of New Candidate Genes in Cases of Human Inherited Thrombocytopenia (CATCH)	nan	COMPLETED
Muscle Tissue Bank for Muscular Dystrophy	nan	COMPLETED
PCD New Gene Discovery	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a MBTPS1 binder may also engage these)

Protein	Name	Similarity
Q9WTZ2	—	1.000	Q9WTZ2 →
Q9Z2A8	—	1.000	Q9Z2A8 →
Q9WTZ3	—	1.000	Q9WTZ3 →
Q0WUG6	—	1.000	Q0WUG6 →
Q5SNQ7	—	0.990	Q5SNQ7 →
Q5XHF8	—	0.990	Q5XHF8 →
F4J8C6	—	0.989	F4J8C6 →
P29119	—	0.988	P29119 →
Q66K08	—	0.988	Q66K08 →
Q6ZQB6	—	0.988	Q6ZQB6 →
G5EFD9	—	0.988	G5EFD9 →
Q84WW3	—	0.987	Q84WW3 →
Q8W4J3	—	0.987	Q8W4J3 →
P19965	—	0.987	P19965 →
Q3U213	—	0.987	Q3U213 →
P08478	—	0.987	P08478 →
Q0VBN2	—	0.987	Q0VBN2 →
Q9FYH7	—	0.987	Q9FYH7 →
Q60HF6	—	0.986	Q60HF6 →
Q9GLD3	—	0.986	Q9GLD3 →
Q86S40	—	0.986	Q86S40 →
Q28193	—	0.986	Q28193 →
PPIP5K2	Inositol hexakisphosphate and diphosphoinositol-pentakisphosphate kinase 2	0.986	landscape →
O22925	—	0.986	O22925 →
F4IYM4	—	0.986	F4IYM4 →
Q2V905	—	0.986	Q2V905 →
Q9JIS8	—	0.985	Q9JIS8 →
Q6GQB9	—	0.985	Q6GQB9 →
P29145	—	0.985	P29145 →
O24326	—	0.985	O24326 →